Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29935256 | 1.00 | POLB (0.42) | POLBHCAR2SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL17912392 | 0.93 | POLB (0.42) | POLBHCAR2SMN1; SMN2RAB9ANPC1 | |
| Formic Acid Methyl Ester SCHEMBL30581051 | 0.92 | POLB (0.36) | POLBHCAR2SMN1; SMN2RAB9ANPC1 | |
| Formic Acid Methyl Ester SCHEMBL29073621 | 0.92 | POLB (0.36) | POLBHCAR2SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL13188227 | 0.86 | RAB9A (0.39) | POLBHCAR2SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL29581626 | 0.86 | RAB9A (0.39) | POLBHCAR2SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL30687154 | 0.85 | SMN1; SMN2 (0.39) | POLBHCAR2SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL26939578 | 0.85 | SMN1; SMN2 (0.39) | POLBHCAR2SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL15932924 | 0.83 | HCAR2 (0.43) | HCAR2CYP2C19KDM4EMEN1ALDH1A1 | |
| SCHEMBL21598711 | 0.81 | HCAR2 (0.42) | HCAR2KDM4EMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107406429-B | Pyridazinone derivatives and their use in the treatment of cancer | 基因泰克公司 | 2021-07-06 | — | — | CN | disclosed |
| US-10239861-B2 | Therapeutic compounds and uses thereof | GENETECH, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-10239861-B2 | Therapeutic compounds and uses thereof | GENETECH, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| EP-3242874-B1 | PYRIDAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | GENENTECH INC (US) | 2018-10-31 | — | — | EP | disclosed |
| US-20180037566-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-02-08 | — | — | US | disclosed |
| US-20180037566-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-02-08 | — | — | US | disclosed |
| US-20180037566-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-02-08 | — | — | US | disclosed |
| EP-3242874-A1 | PYRIDAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2017-11-15 | — | — | EP | disclosed |
| EP-2307371-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2017-10-04 | — | — | EP | disclosed |
| EP-2307371-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2017-10-04 | — | — | EP | disclosed |
| EP-2307371-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| US-20110082129-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-04-07 | — | — | US | disclosed |
| US-20110082129-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-04-07 | — | — | US | disclosed |
| US-20110082129-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-04-07 | — | — | US | disclosed |
| US-7888352-B2 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PIRAMED LIMITED (GB) | 2011-02-15 | — | — | US | disclosed |
| US-20100261698-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| US-20100261698-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| US-20100261698-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| WO-2009156462-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009156462-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082129-A1 | ORGANIC COMPOUNDS | SLCO2B1, SLCO1B1, SLCO1B3 | POLB 745/4885HCAR2 1386/4885SMN1; SMN2 3700/4885 |
| US-20100261698-A1 | ORGANIC COMPOUNDS | SLCO2B1, SLCO1B1, SLCO1B3 | POLB 745/4885HCAR2 1386/4885SMN1; SMN2 3700/4885 |
| US-10239861-B2 | Therapeutic compounds and uses thereof | HDAC10, HDAC6, HDAC11 | POLB 3225/4885HCAR2 2550/4885SMN1; SMN2 208/4885 |
| US-20180037566-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | HDAC10, HDAC6, HDAC11 | POLB 3225/4885HCAR2 2550/4885SMN1; SMN2 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.